HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OTC wart removers

This article was originally published in The Rose Sheet

Executive Summary

FDA finalizes a proposed labeling amendment to the OTC wart remover final monograph for products containing 15% salicylic acid in a karaya gum, glycol plaster vehicle. The amendment, published in the Nov. 23 Federal Register, requires that directions for use include the use of an emery board to "smooth the wart's surface" and application of "a drop of warm water" before applying the medicated plaster. The proposed amendment was issued in January

Latest Headlines
See All
UsernamePublicRestriction

Register

RS001078

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel